AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04621565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
Study NCT03246984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Description: VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
Study NCT04387721 — intervention group
Intervention type: OTHER
Intervention: Kind of trifocal IOL
Description: Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
Study NCT03165500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.
Study NCT03803761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT03165500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid.
Study NCT03803761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT05029076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection
Description: Human glucagon-like peptides-1 analogue
Study NCT05029076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza
Description: Human glucagon-like peptides-1 analogue
Study NCT04366986 — intervention group
Intervention type: OTHER
Intervention: Tested for SARS-CoV-2 (regardless of the result)
Description: This is an observational study with no intervention
Study NCT04366986 — intervention group
Intervention type: OTHER
Intervention: Clinical diagnosis of COVID-19 by a health care professional
Description: This is an observational study with no intervention
Study NCT03904446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Description: 0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
Study NCT03165500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide + Oxygen Gas
Description: Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971).
Study NCT03904446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (placebo)
Description: 1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
Study NCT03797716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Little Journey app
Description: The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery.
Study NCT03640143 — intervention group
Intervention type: OTHER
Intervention: venous blood lead
Description: data about ve,nous blood lead
Study NCT03165500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar extraction
Description: Anxious patients in need of third molar extraction
Study NCT02698787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental sound coding strategy (FAST)
Description: Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
Study NCT02698787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercially available ACE sound coding strategy
Description: Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
Study NCT02445365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoRIC device
Study NCT02445365 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AutoRIC device
Study NCT02637674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus Transplant
Study NCT02411045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Take and send a selfie
Description: Direction to take and send a selfie.
Study NCT02411045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take and send a selfie
Description: Direction to take and send a selfie.
Study NCT02411045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workout gears
Description: Direction to wear workout gears.
Study NCT02411045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Direction to complete a 30 minute workout.
Study NCT00438282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home visitation
Description: Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
Study NCT04627974 — intervention group
Intervention type: DEVICE
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
Study NCT02788929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Charge HR
Description: Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
Study NCT04432272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
Study NCT03878342 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
Study NCT03878342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Radiotherapy
Description: No Irradiation- Active surveillance
Study NCT00982228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
Study NCT00982228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
Study NCT03772678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSALT peptide
Description: novel 16 amino acid peptide
Study NCT03772678 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: saline
Study NCT03104374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT03104374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: Oral tablet
Study NCT03104374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-494
Description: Oral tablet
Study NCT03301506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg Capsule
Description: Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
Study NCT03301506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg Capsule
Description: Subjects will be assigned to a treatment group unless there are tolerability issues.
Study NCT01612949 — intervention group
Intervention type: OTHER
Intervention: photographing head and neck
Description: Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
Study NCT02112734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo daily
Study NCT02519543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given twice daily, once with breakfast and once with supper
Study NCT02519543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
Study NCT04496037 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: See NCT03994783
Study NCT00966628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate
Description: Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
Study NCT00966628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
Study NCT01026857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: PLC colon release tablet 1 g/die for 4 weeks
Study NCT01026857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: PLC colon release tablet 2 g/die for 4 weeks
Study NCT01026857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks
Study NCT01026857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks
Study NCT04915222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural apophyseal glides
Description: Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
Study NCT04915222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical manual traction
Description: Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
Study NCT01956565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle training
Description: Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
Study NCT03209167 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two study-specific questionnaires
Study NCT00913536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using Cone beam CT in patients with Bladder Cancer
Description: Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
Study NCT02297087 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Standard of care based on target(s) identified via GWS.
Study NCT01397669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colon biopsy, lymph node biopsy, lumbar puncture, Leukapheresis, Brain MRI/MRS/DTI
Description: Eligible subjects will undergo a flexible sigmoidoscopy/biopsy and Brain MRI/MRS/DTI at Chulalongkorn University Hospital.~Lumbar puncture, lymph node biopsy, and leukapheresis will be done at TRCARC or IHRI.
Study NCT03735901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMP Levodopa 100mg/Carbidopa 25mg
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.
Study NCT03735901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
Study NCT03635996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS 70 mg
Description: All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
Study NCT03635996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma Nasal Spray Bidose System
Description: Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
Study NCT03092011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
Study NCT03092011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
Study NCT01744366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT01744366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Study NCT00165308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given orally, daily for one year.
Study NCT02290574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperthermia with concurrent chemo-radiation therapy
Study NCT01337505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNO-206
Description: INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
Study NCT02346812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controlled diet without brassica vegetables
Description: Participants will be fed a controlled diet containing foods of a typical American diet.
Study NCT02346812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet with brassica vegetables
Description: Participants will be fed a controlled diet containing foods of a typical American diet.
Study NCT00107614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT PACE + Rituxan
Description: INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
Study NCT02755883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity plus positive affect
Description: Subjects will be randomized to a physical activity goal and will receive the positive affect component.
Study NCT02755883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity plus education
Description: Subjects will be randomized to a physical activity goal and will receive the educational component.